Helen Giza: CEO of FMC leaves abruptly - stock falls sharply
After just under four years at the helm of the dialysis group, Helen Giza is leaving early. According to insiders, the separation was not amicable. The stock is falling sharply.
Helen Giza is leaving her position as CEO of Fresenius Medical Care (FMC) at the end of the week, after serving for almost four years. The company's stock fell by more than 7% following the announcement. Giza's departure was decided unanimously by the board and supervisory board, reportedly due to her inability to present a convincing growth strategy for FMC. Under her leadership, the company struggled with stagnating treatment numbers in the US market, where competitor Davita grew significantly faster.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written; may contain errors — check the original.